The company is quoted as saying that their device, a proprietary dual spring will remove pain by stabilizing the affected spine segment, control motion and abnormal load, and reproduce the kinematics of the segment. Yet, TSB must ask, "how does a device adapt itself to the motion characteristics of each individual patient?" This is an interesting claim!
TSB must speculate that with the FDA mandating additional post-marketing data on dynamic stabilization devices, that early-growth stage companies like Eden are in need of additional capital. The question remains how much? If it is less than $5 million they are going to have some challenges in raising this from an outside investor unless they approach Angels or individual investors. There are many lessons that can be learned from what has transpired during the last year in our industry. TSB wants to know what our readers think about this company's device?